Ipilimumab and Imatinib Mesylate in Advanced Cancer
Public ClinicalTrials.gov record NCT01738139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT01738139
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 68 participants
Conditions and interventions
Conditions
- Advanced Malignant Solid Neoplasm
- C-KIT Tyrosine Kinase Protein Overexpression
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Gastrointestinal Stromal Tumor
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Unresectable Melanoma
- Unresectable Solid Neoplasm
Interventions
- Imatinib Mesylate Drug
- Ipilimumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2013
- Primary completion
- Dec 12, 2022
- Completion
- Dec 12, 2023
- Last update posted
- Mar 20, 2024
2013 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01738139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01738139 live on ClinicalTrials.gov.